Safety and efficacy of bronchoscopic interventions for tracheobronchial mucormycosis: a 27-patient retrospective cohort study

支气管镜介入治疗气管支气管毛霉菌病的安全性和有效性:一项纳入27例患者的回顾性队列研究

阅读:1

Abstract

BACKGROUND: Tracheobronchial mucormycosis (TM) is characterized by tracheobronchial obstruction and stenosis. This study describes our clinical experience with bronchoscopic interventions for managing TM. METHODS: A retrospective analysis of TM patients was conducted at the Affiliated Hospital of Yunnan University, with a focus on clinical manifestations and treatment information. RESULTS: A total of 27 patients with TM were included. CT imaging revealed tracheobronchial stenosis (51.9%) and obstructive lesions (33.3%). Bronchoscopy showed mucosal necrosis (92.6%) and lumen obstruction (22.2%). All patients received at least one endoscopic intervention or bronchoscopic AmBD instillation. Bronchoscopic AmBD instillation was administered to 26 patients (96.3%), averaging 5.7 sessions per patient. Bronchoscopic intervention was performed in 19 patients (70.4%), averaging 4.1 sessions per patient. Common techniques included argon plasma coagulation (12 patients, 33 procedures), electrocautery (13 patients, 21 procedures) and cryotherapy (8 patients, 19 procedures). Mild bleeding occurred in 29.6% of cases during interventions. Follow-up data showed complete remission in 16 patients (59.3%), improvement in 4 (14.8%), and death in 7 (25.9%). CONCLUSION: To date, this constitutes the largest reported case series of TM. Notably, bronchoscopic treatment, comprising AmBD instillation and interventional therapy, serves as a safe and effective approach in the comprehensive management of TM.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。